IP
CSTL icon

Isthmus Partners’s Castle Biosciences CSTL Stock Holding History

Isthmus Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,342
Closed -$210K – 171
2023
Q2 		$210K Sell
15,342
-49,130
-76% -$996K 0.03% 164
2023
Q1 		$1.46M Buy
64,472
+6,660
+12% +$163K 0.21% 100
2022
Q4 		$1.36M Buy
57,812
+1,173
+2% +$27.2K 0.2% 100
2022
Q3 		$1.48M Buy
56,639
+3,925
+7% +$110K 0.25% 89
2022
Q2 		$1.16M Buy
52,714
+12,491
+31% +$290K 0.22% 98
2022
Q1 		$1.8M Buy
40,223
+2,414
+6% +$99.8K 0.3% 74
2021
Q4 		$1.62M Buy
37,809
+28,247
+295% +$1.48M 0.27% 87
2021
Q3 		$636K Sell
9,562
-15
-0.2% -$1.06K 0.12% 122
2021
Q2 		$702K Buy
+9,577
New +$633K 0.12% 119

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Isthmus Partners's CSTL Position: Q3 2023 in Review

Isthmus Partners sold out of Castle Biosciences (CSTL) in Q3 2023, closing a stake of 15,342 shares — an estimated $210K sold.

Isthmus Partners first reported a position in CSTL in Q2 2021 and held it in 9 quarters. The position peaked at $1.8M in Q1 2022. 135 funds tracked by Wall St. Rank hold CSTL as of Q3 2023.

  • Isthmus Partners reported no remaining Castle Biosciences position as of Q3 2023 after selling out during the quarter.
  • Isthmus Partners sold 15,342 Castle Biosciences shares in Q3 2023, an estimated $210K.
  • Isthmus Partners first reported a position in Castle Biosciences in Q2 2021 and held it in 9 quarters.
  • Isthmus Partners's Castle Biosciences position peaked at $1.8M in Q1 2022.
  • 135 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2023.

Based on Isthmus Partners's 13F filing for Q3 2023, filed 14 Nov 2023.